AC
Acadia Pharma
ACAD·NASDAQSan Diego CAFounded 1993900 employees
Mid CapbiotechPublicNeurologyCNSRare Disease
Platform: Neuropsych
Market Cap
$4.5B
All Drugs
3
Clinical Trials
5
Failed / Terminated
0
FDA Approved
0
Stock Price & Catalysts (ACAD)
Loading ACAD stock data...
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| ACA-2691 | ACA-2691 | Phase 3 | 2 | BCMA | CF | ||
| Cevizasiran | ACA-2156 | Phase 1/2 | 2 | GPRC5D | CF | ||
| Bemavorutinib | ACA-1924 | Phase 1/2 | 1 | WEE1 | Cervical CaNSCLC |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (3)